The large multicenter study by Cortellini et al. on 962 PD-L1 positive (≥50%) NSCLC patients receiving pembrolizumab found a positive association of high BMI with objective response rate (ORR) (adjusted OR 1.61 (95% CI 1.04–2.50); p = 0.0208), PFS (adjusted HR 0.61 (95% CI 0.45–0.82); p = 0.0012), and OS (HR 0.70 (95% CI 0.49–0.99); p = 0.0474) [25]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.